OpenFDA + PubChem + ClinicalTrials.gov Integration

FDA Detox Medications & Clinical Research Encyclopedia

Official US Food & Drug Administration (FDA) monographs, PubChem chemical pharmacology profiles, and active ClinicalTrials.gov research studies for addiction recovery and 24/7 medical detox.

FDA-Approved MAT & Detox Medications

Partial Opioid Agonist / MAT

Buprenorphine / Naloxone

FDA Approved (2002)

Brand Names: Suboxone, Zubsolv, Sublocade

FDA Indication:

Maintenance treatment of opioid dependence as part of a complete treatment plan including counseling and psychosocial support.

Receptor Mechanism: Partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor.

🚨 FDA Boxed Warning: WARNING: RISK OF SERIOUS HARM OR DEATH WITH ACCIDENTAL INGESTION; ADDICTION, ABUSE, AND MISUSE.

Package NDCs:54868-5256-012496-1208-10093-5720-56

OpenFDA API SynchronizedFind MAT Centers Offering Suboxone

Full Opioid Agonist / OTP

Methadone Hydrochloride

FDA Approved (1947)

Brand Names: Methadose, Dolophine

FDA Indication:

Detoxification treatment of opioid addiction and maintenance treatment of opioid dependence in certified Opioid Treatment Programs (OTP).

Receptor Mechanism: Full agonist at the mu-opioid receptor and NMDA receptor antagonist.

🚨 FDA Boxed Warning: WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; QT PROLONGATION.

Package NDCs:0054-3556-630054-4571-25

OpenFDA API SynchronizedFind MAT Centers Offering Methadose

Opioid Receptor Antagonist

Naltrexone Extended-Release

FDA Approved (1984 (Oral) / 2006 (Vivitrol Injectable))

Brand Names: Vivitrol, ReVia

FDA Indication:

Prevention of relapse to opioid dependence following opioid detoxification, and treatment of alcohol dependence.

Receptor Mechanism: Competitive antagonist at mu-opioid receptors, blocking euphoric effects of opioids and alcohol.

🚨 FDA Boxed Warning: WARNING: RISK OF HEPATOTOXICITY AT EXCESSIVE DOSES; OPIOID OVERDOSE RISK IF OPIOID BLOCK IS OVERRIDDEN.

Package NDCs:65757-300-010056-0079-01

OpenFDA API SynchronizedFind MAT Centers Offering Vivitrol

Opioid Antagonist / Emergency Reversal

Naloxone Hydrochloride

FDA Approved (1971 (FDA Over-The-Counter Approved 2023))

Brand Names: Narcan, Kloxxado, Zimhi

FDA Indication:

Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression.

Receptor Mechanism: Pure opioid antagonist that competes for and displaces opioids at mu-opioid receptor sites.

Package NDCs:69547-353-0270518-2450-0

OpenFDA API SynchronizedFind MAT Centers Offering Narcan

GABA Modulator / Glutamate Receptor Antagonist

Acamprosate Calcium

FDA Approved (2004)

Brand Names: Campral

FDA Indication:

Maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

Receptor Mechanism: Restores glutamate and GABA balance in the central nervous system altered by chronic alcohol exposure.

Package NDCs:0456-3200-01

OpenFDA API SynchronizedFind MAT Centers Offering Campral

Alcohol Dehydrogenase Inhibitor / Aversion Agent

Disulfiram

FDA Approved (1951)

Brand Names: Antabuse

FDA Indication:

Aid in the management of selected recovery patients who want to remain in a state of enforced sobriety from alcohol.

Receptor Mechanism: Inhibits aldehyde dehydrogenase (ALDH), leading to toxic accumulation of acetaldehyde upon alcohol consumption.

🚨 FDA Boxed Warning: WARNING: DISULFIRAM SHOULD NEVER BE ADMINISTERED TO AN INDIVIDUAL WHEN THEY ARE IN A STATE OF ALCOHOL INTOXICATION.

Package NDCs:0054-0065-25

OpenFDA API SynchronizedFind MAT Centers Offering Antabuse

MAT & Detox Centers Geo-Map

FDA-Approved Medication Assisted Treatment (MAT) Centers

Balanced 50-State coverage with municipal pin markers across all US regions

Filter Municipality:

Active US Clinical Research Trials (ClinicalTrials.gov APIv2)

Live interventional studies currently recruiting patients for addiction and detox research

NCT03745339RECRUITING (PHASE_3)

Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder

Background: People with addictions often find it hard to choose the long-term benefits of abstinence over the short-term effects of using drugs. Researchers think this is partly due to parts of the brain involved in certain types of learning and decision-making. Researchers want to test these basic functions using a simple task with pictures and odors. Objective: To see if performance in a learning task differs between people who have opioid-use disorder and people who don t. Eligibility: Adults 21-60 years old who are willing to fast for at least 6 hours and smell food odors. Those with an opioid-use disorder must either not use for at least 3 weeks or be in treatment. Design: Participants will have 1 visit that will take up to 5 hours. Before the visit, participants will be asked to not eat or drink anything except water for at least 6 hours. At the visit, participants will be checked for signs of intoxication. Participants will give urine and breath samples. Participants will have tests of learning and behavior. They will look at shapes on a computer screen. The shapes will be paired with different food odors. The odors will come from a sterile tube placed under the nose. Participants will have their breathing monitored with a belt around the upper abdomen. About 30 days and 60 days later, participants will be called and asked about their drug use over the past 30 days.

Sponsor: National Institute on Drug Abuse (NIDA)

View Study on ClinicalTrials.gov

NCT05219175RECRUITING (PHASE2)

MDMA for Co-occurring PTSD and OUD After Childbirth

This is an open-label study of the use of MDMA Assisted Therapy for postpartum people with co-occurring Post Traumatic Stress Disorder (PTSD) and Opioid Use Disorder (OUD). The study protocol has been adapted from the Phase 3 studies sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) for PTSD. Due to the high rate of concurrence of PTSD and OUD, people with OUD may experience great benefit from the treatment of their PTSD with MDMA-assisted therapy based on the phase 2 and 3 studies for PTSD. Use of MDMA-assisted therapy in this population has the potential to be of benefit for their OUD and maternal- infant attachment. This study will serve to explore the feasibility and safety of offering MDMA-assisted therapy for treatment of PTSD in postpartum people with opioid use disorder. The CAPs 5 (PTSD) is the primary outcome, the Timeline Follow-Back (TLFB) for opioid use is the secondary outcome and other assessments of opioid use disorder, effects on maternal-infant attachment, social connectedness and other mental health outcomes are exploratory. The study will be conducted at the University of New Mexico Health Sciences Center located in Albuquerque New Mexico. In addition to northern New Mexico being an epicenter of the current opioid use disorder epidemic in the United States there is a long-standing history of multigenerational use of illicit opioids in many communities of northern New Mexico. There are high rates of opioid use disorder on pregnancy and accompanying Neonatal Opioid Use Withdrawal Syndrome (NOWS) in Albuquerque, Santa Fe, and surrounding communities.

Sponsor: University of New Mexico

View Study on ClinicalTrials.gov

NCT06638463RECRUITING (NA)

My Health Coach App RCT

The goal of this clinical trial is to learn if the My Health Coach app helps adults with fetal alcohol spectrum disorders (FASD). The main questions it aims to answer are: Does the My Health Coach app improve the quality of life of adults with FASD? Does the My Health Coach app help adults with FASD manage their day to day life? All participants will be asked to complete 3 sets of surveys: 1) at the study start, 2) at 6 weeks, and 3) at 12 weeks. Half of the participants will be given the app at the study start to use. The other half of participants will get the app after the 12 week surveys are complete. Researchers will compare survey results from people who receive the app right away to those who are in the waitlist group to see if there are changes in quality of life or day to day functioning.

Sponsor: University of Rochester

View Study on ClinicalTrials.gov

NCT06654414RECRUITING (NA)

Adapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke

Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.

Sponsor: Massachusetts General Hospital

View Study on ClinicalTrials.gov

50-State Geographic Directory